Pfizer, Inc. (PFE) is Howe & Rusling Inc.’s 4th Largest Position
Howe & Rusling Inc. grew its stake in Pfizer, Inc. (NYSE:PFE) by 1.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 369,928 shares of the biopharmaceutical company’s stock after purchasing an additional 6,427 shares during the period. Pfizer makes up approximately 2.5% of Howe & Rusling Inc.’s holdings, making the stock its 4th largest holding. Howe & Rusling Inc.’s holdings in Pfizer were worth $12,426,000 as of its most recent SEC filing.
Several other hedge funds also recently added to or reduced their stakes in the company. Northstar Group Inc. grew its stake in shares of Pfizer by 0.4% in the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 35 shares during the period. Stone House Investment Management LLC grew its stake in shares of Pfizer by 0.9% in the 1st quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock valued at $245,000 after purchasing an additional 66 shares during the period. Naples Global Advisors LLC grew its stake in shares of Pfizer by 0.3% in the 1st quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 79 shares during the period. Alpha Windward LLC grew its stake in shares of Pfizer by 1.1% in the 1st quarter. Alpha Windward LLC now owns 8,387 shares of the biopharmaceutical company’s stock valued at $287,000 after purchasing an additional 89 shares during the period. Finally, Asset Planning Services Ltd. grew its stake in shares of Pfizer by 4.9% in the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 137 shares during the period. Institutional investors own 69.00% of the company’s stock.
In other Pfizer news, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ian C. Read sold 197,168 shares of the business’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $34.00, for a total transaction of $6,703,712.00. Following the sale, the chief executive officer now directly owns 580,318 shares in the company, valued at approximately $19,730,812. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 464,521 shares of company stock worth $15,813,961. Insiders own 0.06% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a research note on Tuesday, October 3rd. Berenberg Bank set a $39.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Tuesday, August 1st. Morgan Stanley reiterated a “neutral” rating and issued a $35.00 price objective (down from $38.00) on shares of Pfizer in a research note on Monday, June 12th. Finally, Cowen and Company set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Monday, August 14th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $38.21.
ILLEGAL ACTIVITY WARNING: “Pfizer, Inc. (PFE) is Howe & Rusling Inc.’s 4th Largest Position” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.watchlistnews.com/pfizer-inc-pfe-is-howe-rusling-inc-s-4th-largest-position/1618256.html.
Shares of Pfizer, Inc. (PFE) traded up 0.14% on Friday, reaching $36.05. The company’s stock had a trading volume of 12,060,086 shares. The company has a market cap of $214.40 billion, a PE ratio of 26.37 and a beta of 1.00. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $36.24. The firm has a 50 day moving average of $34.72 and a 200 day moving average of $33.69.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.64 earnings per share. Analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.55%. Pfizer’s payout ratio is presently 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.